Compass Point downgraded Horizon Technology (HRZN) to Sell from Neutral with a $10 price target after Evelo Biosciences (EVLO) announced its Phase 2 clinical study with EDP2939 in moderate psoriasis did not achieve the study’s primary endpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRZN:
